
1. cell rep. 2015 sep 29;12(12):1978-85. doi: 10.1016/j.celrep.2015.08.037. epub
2015 sep 10.

ptpn11 central node intrinsic acquired resistance targeted cancer 
drugs.

prahallad a(1), heynen gj(1), germano g(2), willems sm(3), evers b(1), vecchione 
l(1), gambino v(1), lieftink c(1), beijersbergen rl(1), di nicolantonio f(4),
bardelli a(4), bernards r(5).

author information: 
(1)cancer genomics centre netherlands, netherlands cancer institute,
plesmanlaan 121, 1066 cx amsterdam, netherlands.
(2)candiolo cancer institute - fpo, irccs, str. prov. 142 km 3.95, 10060
candiolo, torino, italy; firc institute molecular oncology (ifom), via
adamello 16, 20139 milan, italy.
(3)cancer genomics centre netherlands, netherlands cancer institute,
plesmanlaan 121, 1066 cx amsterdam, netherlands; department pathology,
university medical centre utrecht, heidelberglaan 100, 3584 cx utrecht, the
netherlands.
(4)candiolo cancer institute - fpo, irccs, str. prov. 142 km 3.95, 10060
candiolo, torino, italy; department oncology, university torino, str. prov.
142 km 3.95, 10060 candiolo, torino, italy.
(5)cancer genomics centre netherlands, netherlands cancer institute,
plesmanlaan 121, 1066 cx amsterdam, netherlands. electronic address:
r.bernards@nki.nl.

most braf (v600e) mutant melanomas sensitive selective braf inhibitors,
but braf mutant colon cancers intrinsically resistant drugs 
of feedback activation egfr. performed rna-interference-based genetic
screen braf mutant colon cancer cells search phosphatases whose
knockdown induces sensitivity braf inhibition. found suppression of
protein tyrosine phosphatase non-receptor type 11 (ptpn11) confers sensitivity to
braf inhibitors colon cancer. mechanistically, found inhibition of
ptpn11 blocks signaling receptor tyrosine kinases (rtks) ras-mek-erk 
pathway. ptpn11 suppression lethal cells driven activated rtks 
and prevents acquired resistance targeted cancer drugs results rtk
activation. findings identify ptpn11 drug target combat both
intrinsic acquired resistance several targeted cancer drugs. moreover,
activated ptpn11 serve biomarker drug resistance resulting rtk
activation.

copyright Â© 2015 authors. published elsevier inc. rights reserved.

doi: 10.1016/j.celrep.2015.08.037 
pmid: 26365186  [indexed medline]

